Cardiac Biomarker Diagnostic Kits Global Market

Cardiac biomarker diagnostic kits are increasingly gaining importance as these prove to be efficient for the measurement of biomarkers (which are released into the blood) in order to risk stratify, diagnose, monitor as well as manage monitor and manage patients with suspected cardiac issues such as acute coronary syndrome, cardiac ischemia, and others. Also, cardiac biomarkers have evolved as crucial tools in the field of cardiology for primary and secondary prevention, diagnosis, and management of acute myocardial infarction, as well as risk stratification and diagnosis of heart failure.

According to a market report published by Bizwit Research & Consulting, LLP, the global cardiac biomarker diagnostic kits market is valued at approximately USD 2.45 billion in 2020 and is anticipated to grow with a healthy growth rate of nearly 5.14% over the forecast period 2021-2027.

The rising prevalence of cardiovascular disorders and government funding for cardiovascular disease treatment are some of the factors that are expected to significantly contribute to the growth of the global cardiac biomarker diagnostic kits market during the forecast period. In addition, point-of-care testing (POCT) with cardiac biomarkers and integration of cardiology & IT provides lucrative growth opportunities to the market. However, side effects associated with cardiac biomarkers are expected to hamper the growth of the global cardiac biomarker diagnostic kits market during the forecast years.

Incidences of cardiovascular diseases such as coronary heart disease, cerebrovascular disease, peripheral arterial disease, rheumatic heart disease, congenital heart disease, deep vein thrombosis and pulmonary embolism, and others increase the need for proper and accurate diagnosis which increases the demand for cardiac biomarker diagnostic kits. According to an article published by the World Health Organization in 2021, cardiovascular diseases are the leading cause of death across the globe. Nearly 17.9 million people died from cardiovascular diseases in 2019, which accounted for 32% of all deaths worldwide. Of these deaths, about 85% were due to heart stroke and attack. This demands advanced detection methods and tools such as diagnostic kits and hence contributes towards the market growth.

Global Cardiac Biomarker Diagnostic Kits Market Size Study, by Product Type (Reagents and Kits, and Instruments,), by Disease Indication (Angina Pectoris, Myocardial Infarction, Cardiac Heart Failure, and Others), By End-User (Hospitals, Diagnostic Centers, Clinics, and Others) and Regional Forecasts 2021-2027

The total market revenue is calculated on the basis of revenue generated through sales of diagnostic kits to track cardiac biomarkers. However, any revenue generated through maintenance and repair of testing instruments is excluded from the report. Major companies covered under the report include Roche Diagnostics Limited, Abbott Laboratories, Siemens AG, Beckman Coulter Diagnostics, Biomerieux SA, Alere Inc., Bio-Rad Laboratories, Ortho Clinical Diagnostics, Randox Laboratories Ltd., and Guangzhou Wondfo Biotech Co., Ltd. Other popular regional players across various countries are also considered for revenue calculation.

Review the reports at

Data drives better decisions

Bizwit Research & Consulting LLP